While injection sclerotherapy has been accepted as the treatment of choice for acute variceal bleeding, its role as a definitive long-term treatment modality has not yet been clearly defined. This paper will critically analyse the current status of this technique, now widely used, and a comparison will be made with conventional medical management. The review will be based on the 10 years' Cape Town experience and the published series on this subject. A long-term management strategy will also be discussed.
INTRODUCTION
Dissatisfaction with the results of management of bleeding oesophageal varices at Groote Schuur Hospital in the seventies 1'2 prompted the Liver Research Group in Cape Town to launch prospective studies to evaluate the role of sclerotherapy both during the acute bleeding episode and as an alternative definitive form of long-term treatment4.
LONG-TERM SCLEROTHERAPY VERSUS MEDICAL TREATMENT
In the first long-term controlled study, repeated sclerotherapy (with the aim of eradication of varices) was compared to a medical management regimen. Emergency sclerotherapy was however instituted when balloon tamponade was required to control recurrent bleeding episodes. Although recurrent acute variceal bleeds were appreciably reduced by sclerotherapy, and eradication of varices was usually possible, overall mortality was not reduced4 '5. Failure to improve survival was also reported in two further studies 6'7 where the control groups did not receive emergency salvage sclerotherapy for recurrent 9 and Cello et al. 3 would seem to give the best results. Our current long-term management policy is to submit patients to a weekly sclerotherapy session with the aim of early eradication, appreciating that factors such as the development of injection site ulceration and patient compliance frequently interfere with the sclerotherapy programme. After eradication of the varices patients should be followed up at six to 12 month intervals and, if varices recur, an aggressive sclerotherapy schedule should be instituted again. It is hoped that in the future the addition of effective pharmacological agents will improve the results of sclerotherapy both in terms of facilitating earlier eradication and prevention of recurrence.
